Evidence map›Paper›PMID 28146103›Full record

ArticleMolecules (Basel, Switzerland)2017

Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives.

Laure-Estelle Cassagnes, Nambinina Rakotoarivelo, Serena Sirigu, Pierre Pério, Ennaji Najahi, Léonard M G Chavas, Andrew Thompson, Régis Gayon, Gilles Ferry, Jean A Boutin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Laure-Estelle CassagnesUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. laureestelle.cassagnes@gmail.com.
Nambinina RakotoariveloUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. nambine0508@yahoo.fr.
Serena SiriguSynchrotron SOLEIL, L'Orme des Merisiers, BP 48 Saint-Aubin, 91190 Gif sur Yvette CEDEX, France. serena.sirigu@synchrotron-soleil.fr.
Pierre PérioUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. pierre.perio@univ-tlse3.fr.
Ennaji NajahiUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. najahimco@yahoo.fr.
Léonard M G ChavasSynchrotron SOLEIL, L'Orme des Merisiers, BP 48 Saint-Aubin, 91190 Gif sur Yvette CEDEX, France. leonard.chavas@synchrotron-soleil.fr.
Andrew ThompsonSynchrotron SOLEIL, L'Orme des Merisiers, BP 48 Saint-Aubin, 91190 Gif sur Yvette CEDEX, France. andrew.thompson@synchrotron-soleil.fr.
Régis GayonVectalys S.A., Parc Technologique du Canal, Bâtiment Canal Biotech 2, 3, Rue des Satellites, 31400 Toulouse, France. regis.gayon@vectalys.com.
Gilles FerryExpertise Biotechnologie, Chimie, Biologie, Institut de Recherches Servier, 125, Chemin de Ronde, 78290 Croissy sur Seine, France. gilles.ferry@servier.com.
Jean A BoutinExpertise Biotechnologie, Chimie, Biologie, Institut de Recherches Servier, 125, Chemin de Ronde, 78290 Croissy sur Seine, France. jean.boutin@servier.fr.
Alexis ValentinUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. alexis.valentin@univ-tlse3.fr.
Karine ReybierUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. karine.reybier-vuattoux@univ-tlse3.fr.
Françoise NepveuUMR 152 Pharma-Dev, Université de Toulouse, IRD, UPS, 31062 Toulouse, France. francoise.nepveu@univ-tlse3.fr.
Université Toulouse III - Paul Sabatier · FRSynchrotron soleil · FRServier (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indolone-N-oxides have antiplasmodial properties against Plasmodium falciparum at the erythrocytic stage, with IC50 values in the nanomolar range. The mechanism of action of indolone derivatives involves the production of free radicals, which follows their bioreduction by an unknown mechanism. In this study, we hypothesized that human quinone reductase 2 (hQR2), known to act as a flavin redox switch upon binding to the broadly used antimalarial chloroquine, could be involved in the activity of the redox-active indolone derivatives. Therefore, we investigated the role of hQR2 in the reduction of indolone derivatives. We analyzed the interaction between hQR2 and several indolone-type derivatives by examining enzymatic kinetics, the substrate/protein complex structure with X-ray diffraction analysis, and the production of free radicals with electron paramagnetic resonance. The reduction of each compound in cells overexpressing hQR2 was compared to its reduction in naïve cells. This process could be inhibited by the specific hQR2 inhibitor, S29434. These results confirmed that the anti-malarial activity of indolone-type derivatives was linked to their ability to serve as hQR2 substrates and not as hQR2 inhibitors as reported for chloroquine, leading to the possibility that substrate of hQR2 could be considered as a new avenue for the design of new antimalarial compounds.

Indexed as

AnimalsAntimalarialsCHO CellsCricetulusFree RadicalsHumansIndolesModels, MolecularMolecular StructurePlasmodium falciparumProtein BindingProtein ConformationQuinone ReductasesReactive Oxygen SpeciesAntimalarialsFree RadicalsIndolesQuinone ReductasesReactive Oxygen Specieshuman quinone reductase 2indolonesinhibitormalariamechanism

Identifiers

PMID28146103
PMCPMC6155775
OpenAlexW2582774104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.